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CASE REPORT
The physician and hereditary angioedema 
friend or foe: 62-year diagnostic delay 
and iatrogenic procedures
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Abstract 
Background: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant dis-
ease characterized by episodes of acute subcutaneous swelling, and/or recurrent severe abdominal pain. The disease 
is potentially fatal if the upper-airway is involved. Iatrogenic harm can occur if HAE is not considered in the differential 
diagnosis, the specialists are not aware of the natural history, diagnosis and treatment of HAE, or as a result of unnec-
essary surgical and other iatrogenic interventions.
Case presentation: We present the case of a 72-year-old man who began suffering recurrent abdominal pain at the 
age of 8 years. The pain led to frequent emergency department visits, three emergency surgical interventions, and 5 
endoscopies before C1-INH-HAE was diagnosed at the age of 70. Infrequent subcutaneous swellings were attributed 
to unknown allergic reactions that were not related to the primary diagnosis of abdominal pain. Family history was 
positive for recurrent abdominal pain and angioedema but was ignored until the propositus’ grandson developed 
recurrent severe oro-facial edema attacks. The boy’s mother searched the worldwide web and found educational 
materials on a patient association website. She suggested complement C4 and C1-INH testing that led to the appro-
priate diagnosis of C1-INH-HAE type 1 in her son and his grandfather.
Conclusion: This report emphasizes the importance of accurately evaluating personal and family history in patients 
with a long history of recurrent, acute, severe but medically unexplained abdominal pain and cutaneous swellings. 
Here, the diagnosis of HAE was overlooked for 62 years and the focus on abdominal complaints led to numerous sur-
gical interventions without consideration of the full differential diagnosis. Screening family members from all genera-
tions for unrecognized angioedema, abdominal pain, and measurement of C1-INH and C4 are essential for accurate 
and timely diagnosis of HAE.
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Background
Hereditary angioedema (HAE) is a rare autosomal domi-
nant disease characterized by recurrent swellings of the 
extremities, oro-facial-pharyngeal zones, upper airways, 
and genitalia [1]. These lead to frequent emergency 
department (ER) visits. More than 90% of subjects with 
cutaneous angioedema episodes also develop recurrent 
edema of the intestinal mucosa causing severe abdomi-
nal pain [2, 3]. The most common and best-characterized 
form of HAE is due to mutations of the C1 inhibitor 
(C1-INH) gene (SERPING1) resulting in reduced (below 
50% of normal) C1-INH plasma levels (C1-INH-
HAE type 1) and/or function (C1-INH-HAE type 2). 
Marked consumption of complement C4 to below 
10 mg/100 mL supports the diagnosis. C4 measurement 
is a good screening test that is performed by most clinical 
laboratories.
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Hereditary angioedema is a potentially life threatening 
disease, with 1–3% of all angioedema episodes affecting 
the larynx and upper airways. In the absence of appro-
priate diagnosis and treatment, 25% of patients die from 
asphyxiation [4–6]. The burden of HAE has a huge geo-
graphical discrepancy due to differences in treatment 
availability. Beginning in 2009 new drugs for C1-INH-
HAE were approved in western Europe and North Amer-
ica. Treatment availability has decreased mortality to 
near zero if the correct diagnosis is known. Therefore, it 
is essential to increase awareness of how to diagnose and 
treat HAE and to reduce any delays in diagnosis. Never-
theless, extreme delay is still a major issue, even in devel-
oped countries with good health care systems [7–9].
In countries where new generation treatments are not 
available, awareness of the disease is minimal, patient 
lives are disrupted, and mortality for HAE remains high. 
We highlight this situation by reporting a patient with a 
62-year history of typical subcutaneous and abdominal 
symptoms who had numerous gastrointestinal interven-
tions, and whose diagnosis was suggested by a family 
member who noted the positive family history.
Case presentation
A 72-year old man suffered from recurrent abdominal 
attacks beginning at age 8 (Fig. 1, Timeline). The attacks 
usually began as a colic-like periumbilical pain that 
spread to involve the entire abdomen, mimicking abdom-
inal guarding, and progressing with vomiting, diarrhea, 
debilitation, and often syncope. During adolescence, 
infrequent subcutaneous angioedema episodes occurred 
and could not be related to any specific cause. Some-
times, an ill-defined, non-pruritic skin “rash” occurred 
in various locations. There was no evidence of any atopic 
condition such as allergic rhino-conjunctivitis, atopic 
dermatitis or asthma, and no specific tests for allergy 
were performed. Family history was positive as his father 
had similar symptoms; however, this evidence went 
ignored by the consulting physicians. Later, our patient 
started to experience peripheral subcutaneous swellings, 
often as a result of minor traumatic stimuli. Conventional 
anti-allergic therapy with antihistamines, with or without 
corticosteroids, had scarce benefit. No matter the treat-
ment, these attacks lasted for 48–72 h, or more. He had 
frequent ER visits over his entire lifetime.
In 1971, at the age of 26, he underwent surgery with 
a diagnosis of catarrhal appendicitis. There is a lim-
ited clinical documentation for the next 30  years, dur-
ing which he experienced his stereotypical, recurrent 
abdominal episodes and had 4–6 hospital admissions per 
year with no conclusive diagnosis.
Recurrent abdominal symptoms in February 2010, 
led to emergency colonoscopy with removal of a benign 
polyp. No other diagnosis was made.
One month later, in March 2010, the recurrent acute 
abdominal pain was diagnosed as acalculous cholecysti-
tis. Ultrasound examination showed ascites in all abdom-
inal compartments, and radiography showed hydro-aeric 
shadows in the intestinal region. Laparoscopic cholecys-
tectomy was performed without objective evidence for 
gallbladder lithiasis. Diagnosis at discharge was catarrhal 
cholecystitis and laparoscopic cholecystectomy.
Two weeks later the patient was hospitalized for 
severe abdominal pain interpreted as mechanical ileus. 
Ascites and hydro-aeric shadows were present. Com-
puted tomography (CT) showed 13 mm thickening of the 
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jejunal wall. Symptoms resolved after 7 days of conserva-
tive spasmolytic and analgesic treatment.
Seven weeks later in June 2010 he was hospitalized 
with the identical clinical picture and given the diagnosis 
of “recurrent mechanical ileus.” An “urticarial rash” was 
documented on admission. Physical examination found 
extensive abdominal tympanism, with radiographic 
hydro-aeric shadows in the left side of the abdomen. 
Symptoms resolved after 5 days of conservative therapy.
In October 2010 he presented with analogous symp-
toms. Diagnosis this time was presumed to be an acute 
volvulus and he had an emergency median and inferior 
laparotomy. The procedure was described as “manual 
fixation of a volvulus without intestinal resection, plus 
debridement of peritoneal adhesions.” The post-operative 
period was complicated by severe abdominal pain that 
was resistant to combined analgesic therapy with opioids 
and nonsteroidal drugs (NSAIDs).
In 2011 and 2012, the patient’s recurrent abdominal 
pain attacks lead to 4 emergency colonoscopies and 1 
gastroscopy. Several benign polyps were extirpated, but 
there was no indication they were related to the symp-
toms. Between 2013 and 2015, repeated emergency visits 
resulted in hospital admissions to Departments of Inter-
nal Medicine, Gastroenterology, and Intensive Care, with 
no conclusive diagnosis at discharge. Additional surgery 
and endoscopies were proposed, but were refused by 
the patient based on his previous experiences of mul-
tiple ineffective, and in fact, worsening his suffering 
interventions.
In 2015 one of his grandsons developed episodes of 
recurrent, disfiguring subcutaneous oro-facial angi-
oedema, abdominal pain and swellings of the oro-phar-
yngeal mucosa (lips, epi- and hypopharynx, and uvula) 
that lasted up to 1  week, and were totally resistant to 
conventional anti-allergic therapy with epinephrine, cor-
ticosteroids and antihistamines. No association with an 
allergic condition could be made: no food, drug, or other 
triggers precipitated the episodes. They seemed to be 
unpredictable, or in some occasions provoked by trau-
matic stimuli. The child had frequent emergency visits 
and hospitalizations of 3–7  days’ duration. His mother 
noticed that similar symptoms of facial swellings and 
abdominal pain occurred in at least three generations of 
her husband’s family. She searched the internet for these 
symptoms and began to suspect hereditary angioedema. 
She requested that her son have C4 and C3 measured. 
The results showed low C4 and normal C3, so the pre-
sumptive diagnosis of HAE was made and the boy was 
referred to our tertiary center. Further evaluation con-
firmed the diagnosis of C1-INH-HAE type I in the child 
and 6 other family members (Fig. 2, Family tree). Specific 
treatment for bradykinin-mediated angioedema, C1-INH 
concentrate on demand: recombinant in the adults 
 (Ruconest®, conestat alfa), and plasma-derived in the 
children  (Berinert®) was introduced in all family mem-
bers with good clinical outcomes.
Discussion
C1-INH-HAE has a clear-cut clinical presentation of 
recurrent cutaneous swellings, abdominal pain and phar-
yngeal/laryngeal edema. Erythema marginatum is a typi-
cal manifestation that often precedes the angioedema, 
and could be easily mistaken for urticaria by non-spe-
cialists, although non-pruritic. The lips, face and phar-
ynx become severely edematous as the loose connective 
tissue fills with extravasated plasma due to the localized 
vascular leakage. Unlike histaminergic angioedema (as in 
urticaria or other allergic conditions), the edema persists 
for several days.
Angioedema of the serosa and walls of the intestines 
leads to thickening of the visceral walls, compression of 
the lumen, and clinical picture of temporary ileus lead-
ing to emesis and diarrhea. Serosal extravasation leads to 
ascites that is recurrent and spontaneously resolving. The 
combination of these oro-facial, peripheral cutaneous 
and gastrointestinal manifestations places HAE firmly 
in the routine differential diagnosis of recurrent unex-
plained abdominal pain [10]. Furthermore, the positive 
family history increases the probability for this otherwise 
rare condition, as the disease segregates in family mem-
bers with the congenital plasma deficiency of C1-INH 
and subsequent consumption of C4.
The skin manifestations recognized as prodromes of 
angioedema could contribute to the difficulty of diag-
nosing HAE. Erythema marginatum is a typical mani-
festation that precedes the occurrence of angioedema 
attacks in C1-INH-HAE. It can be easily mistaken for 
hives and lead to the misdiagnosis of allergy or chronic 
urticaria [11]. In urticaria degranulation of mast cells 
by IgE (atopy), autoantibodies, and other agents such 
as nonsteroidal anti-inflammatory drugs and intrave-
nous contrast dyes lead to release of histamine in the 
superficial dermis and mucosal lamina propria. Hista-
mine causes an intense pruritus with localized vascular 
leak, but the duration of the urticaria is generally less 
than 24 h. Mast cell disorders respond well to antihis-
tamines, corticosteroids, and, in an, emergency, epi-
nephrine. C1-INH-HAE is not a mast cell mediated 
disorder, as these medications are ineffective, as seen 
in our patient. In HAE trauma, infection and other 
unknown triggers lead to activation of plasma kallikrein 
by factor XIIa and subsequent massive release of brady-
kinin from cleaved high molecular weight kininogen 
when their controller, C1-INH, is deficient [12]. Brad-
ykinin leads to a painful sensation, and causes deep 
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dermal and mucosal vasodilation, vascular leak, and 
plasma extravasation. This is supported by the efficacy 
of icatibant, a bradykinin B2 receptor antagonist, in 
C1-INH-HAE [13]. The histological difference between 
histamine H1 and bradykinin B2 receptor bearing neu-
rons and vessels in the upper versus lower dermis, 
respectively, contributes to the clinical and etiological 
distinctions between histaminergic and bradykinin-
mediated angioedema. This difference has an important 
implication as it explains the uselessness of antihista-
minics and other treatments targeted to mast cells ver-
sus bradykinin antagonist and C1-INH concentrate. 
C1-INH (plasma-derived and recombinant forms) and 
bradykinin antagonists are now the standard of care for 
acute attacks of C1-INH-HAE [14]. Failure to use these 
drugs exposes HAE patients to the risk of death and 
extensive suffering. Several bradykinin-targeted drugs 
have become available in the last 10 years and new ones 
are moving through the development pipeline. Unfor-
tunately, all these new therapies are extremely expen-
sive and have limited or no availability in low-income 
countries [15]. In Bulgaria, the country of our patient, 
recombinant C1-INH became available for HAE treat-
ment in 2013 and still has limited availability and 
strictly controlled access for patients diagnosed with 
C1-INH-HAE Type 1 and 2. The limited therapeutic 
options for angioedema may reduce the motivation to 
reach a diagnosis for both patients and physicians [16], 
and provides an additional obstacle to reach correct 
diagnosis.
Our patient developed a complete presentation of 
HAE at the age of 8, but was not diagnosed for over 
60  years. This was despite over countless emergency 
department and hospital admissions, innumerable 
clinical evaluations by many teams of physicians over 
the decades, invasive surgical and endoscopic inter-
ventions. Our patient confirms that physicians may 
still ignore the medical dogma of carefully investigat-
ing family history. His delay in diagnosis is not unusual, 
as the average time to diagnosis of HAE is between 
12.1 and 12.9  years [17, 18]. The delay may be longer 
if abdominal symptoms predominant the clinical pres-
entation. Undiagnosed patients have up to nine times 
higher risk of asphyxiation [5] and an overall risk of 
death from laryngeal edema of 25%. The rate of iatro-
genic harm due to unnecessary surgical procedures 
in diagnosed and undiagnosed patients is not known, 
though may be substantial [19]. This is another rea-
son to understand the pathophysiology of HAE, aim to 
accelerate the time to diagnosis, and provide life-saving 
modern therapies.
Inheritance of C1-INH-HAE is autosomal dominant, 
but only 75% have an affected family member. Diag-
nosis is confirmed by plasma deficiency of C1-INH 
protein level and function. The remaining 25% of 
index cases are sporadic and due to de novo muta-
tions in SERPING1 [20]. Because these patients have 
HAE affected male 
Unaffected female 
Mother performed the internet 
search, leading to HAE diagnosis 
Propositus’ grandson presenng 
severe oro-facial HAE aacks 
Fig. 2 Family tree
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no affected ancestors, their family history will be nega-
tive and it may be more difficult to reach the diagno-
sis. However, even patients with positive family history 
can have delayed diagnosis, as for example in an Iranian 
population where those with positive family history 
have a longer delay compared to patients with no such 
anamnesis [21].
The differential diagnosis of HAE includes acquired 
C1-INH deficiency. It has a similar clinical presenta-
tion but presents at older ages [22]. Autoantibodies to 
C1-INH may be responsible and occur as a paraneoplas-
tic syndrome. The acquired form can have low C1q lev-
els, while these remain normal in hereditary angioedema 
[23].
An integral part of this case was the path to discovery 
of the diagnosis. The unaffected mother of a sick child 
performed the internet search that suggested the correct 
diagnosis. This highlights the importance of accurate, 
publically available information provided by patient asso-
ciations (http://www.haei.org) and the general paradigm 
shift towards patient-centric, individualized diagnosis 
and treatment in rare diseases. Educational programs 
for patients increase the probability that they and their 
relatives become knowledgeable about the disease. 
These programs and social media become tools to inte-
grate medical education directly to patients [24, 25]. In 
addition, providing up-to-date medical information for 
emergency physicians, gastroenterologists, internists, 
family doctors, allergists and others who see angioedema 
patients is essential and should be widely encouraged, as 
such common efforts could help prevent further HAE 
misdiagnosis, delay of adequate medical care, iatrogenic 
procedures, and complications.
Special attention must be dedicated to address the 
familial inheritance of the condition, as HAE affects the 
lives of many consecutive generations. Therefore, whole-
sale screening by history and physical, with targeted 
C1-INH and C4 testing should become the standard of 
practice for all family members of a patient with HAE.
Abbreviations
HAE: hereditary angioedema; C1-INH: complement C1 inhibitor; C1-INH-HAE: 
hereditary angioedema due to C1-inhibitor deficiency.
Authors’ contributions
AV and MS analyzed and interpreted the patient data; AV drafted the manu-
script; MC and JB reviewed and edited the manuscript, MS confirmed the 
diagnosis in the patient and family. All authors read and approved the final 
manuscript.
Author details
1 Clinical Center of Allergology, Clinic of Allergy and Asthma, University Hospi-
tal “Alexandrovska”, Medical University of Sofia, 1, Georgi Sofiiski Str., 1431 Sofia, 
Bulgaria. 2 Department of Biomedical and Clinical Sciences, ASST Fateben-
efratelli Sacco, Luigi Sacco Hospital-Polo Ospedaliero, University of Milan, 
Milan, Italy. 3 Division of Rheumatology, Immunology and Allergy, Department 
of Medicine, Georgetown University, Washington, DC, USA. 
Acknowledgements
We are grateful to the family members for their consent and collaboration in 
preparing this publication which we hope will prevent misdiagnosis of HAE 
and iatrogenic complications.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
No datasets were generated or archived for this publication. Additional details 
may be obtained from the corresponding author as long as individual data 
privacy is maintained.
Consent for publication
Consent for this publication was obtained from the subject and family 
members.
Ethics approval and consent to participate
Approval and consent for this case presentation was obtained from the sub-
ject and the family members, and the local IRB.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 31 January 2018   Accepted: 10 July 2018
References
 1. Moellman JJ, Bernstein JA. Diagnosis and management of hereditary 
angioedema: an emergency medicine perspective. J Emerg Med. 
2012;43(2):391–400.
 2. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Far-
kas H, Grumach A, Kaplan AP, et al. Classification, diagnosis, and approach 
to treatment for angioedema: consensus report from the Hereditary 
Angioedema International Working Group. Allergy. 2014;69(5):602–16.
 3. Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the 
diagnosis and management of abdominal manifestations of hereditary 
angioedema. Eur J Gastroenterol Hepatol. 2012;24(4):353–61.
 4. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new find-
ings concerning symptoms, affected organs, and course. Am J Med. 
2006;119(3):267–74.
 5. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in heredi-
tary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 
2012;130(3):692–7.
 6. Zanichelli A, Mansi M, Azin GM, Wu MA, Periti G, Casazza G, Vacchini 
R, Suffritti C, Cicardi M. Efficacy of on-demand treatment in reducing 
morbidity in patients with hereditary angioedema due to C1 inhibitor 
deficiency. Allergy. 2015;70(12):1553–8.
 7. Martinez-Saguer I, Escuriola Ettingshausen C. Delayed diagnosis of 
hereditary angioedema: thirty-nine years of inadequate treatment. Ann 
Allergy Asthma Immunol. 2016;117(5):554–6.
 8. Peterson MP, Bygum A. Hereditary angioedema: 44 years of diagnostic 
delay. Dermatol Online J 2016; 22(4).
 9. Berger J, Carroll MP Jr, Champoux E, Coop CA. Extremely delayed diag-
nosis of type II hereditary angioedema: case report and review of the 
literature. Mil Med. 2018. https ://doi.org/10.1093/milme d/usy03 1.
 10. Gábos G, Dobru D, Mihály E, Bara N, Dumitrache C, Popa R, Nădășan V, 
Moldovan D. Recurrent ascites: a need to evaluate for hereditary angio-
oedema. Lancet. 2017;390(10107):2119–20.
 11. Rasmussen ER, de Freitas PV, Bygum A. Urticaria and prodromal symp-
toms including erythema marginatum in Danish patients with hereditary 
angioedema. Acta Derm Venereol. 2016;96(3):373–6.
 12. Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angi-
oedema. Pediatr Allergy Immunol Pulmonol. 2014;27(4):159–63.
Page 6 of 6Valerieva et al. Allergy Asthma Clin Immunol  (2018) 14:75 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 13. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork 
K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, 
Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, 
Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, 
Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, 
Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, 
Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton 
D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, 
Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen 
K, Fan WT. Icatibant, a New Bradykinin-receptor antagonist, in hereditary 
angioedema. N Engl J Med. 2010;363(6):532–41.
 14. Wu MA, Zanichelli A, Mansi M, Cicardi M. Current treatment options 
for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin 
Pharmacother. 2016;17(1):27–40.
 15. Longhurst H, Bygum A. The humanistic, societal, and pharmaco-
economic burden of angioedema. Clin Rev Allergy Immunol. 
2016;51(2):230–9.
 16. Lumry WR. Pharmacoeconomics of Orphan Disease Treatment with 
a Focus on Hereditary Angioedema. Immunol Allergy Clin North Am. 
2017;37(3):617–28.
 17. Speletas M, Szilagyi A, Psarros F, Moldovan D, Magerl M, Kompoti M, 
Gramoustianou E, Bors A, Mihaly E, Tordai A, et al. Hereditary angioedema: 
molecular and clinical differences among European populations. J Allergy 
Clin Immunol. 2015;135(2):570–3.
 18. Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angi-
oedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy 
Asthma Clin Immunol. 2013;9(1):29.
 19. Persiani R, Biondi A, Buccelletti F, Rausei S, Silveri NG. Unusual acute abdo-
men: to operate or not to operate? Lancet. 2006;367(9521):1548.
 20. Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agos-
toni A, Tosi M. Frequent de novo mutations and exon deletions in the 
C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 
2000;106(6):1147–54.
 21. Kargarsharif FMN, Zahedi Fard S, Fazlollahi MR, Ayazi M, Mohammadza-
deh I, Nabavi M, Bemanian MH, Fayezi A, Movahedi M, Heidarzadeh M, 
Kalantari N, Arefimehr S, Saghafi S, Pourpak Z. Type I and type II hereditary 
angioedema: clinical and laboratory findings in iranian patients. Arch Iran 
Med. 2015;18(7):425–9.
 22. Castelli R, Zanichelli A, Cicardi M, Cugno M. Acquired C1-inhibitor 
deficiency and lymphoproliferative disorders: a tight relationship. Crit Rev 
Oncol Hematol. 2013;87(3):323–32.
 23. Wu MA, Castelli R. The Janus faces of acquired angioedema: C1-inhibitor 
deficiency, lymphoproliferation and autoimmunity. Clin Chem Lab Med. 
2016;54(2):207–14.
 24. Zuraw BL, Christiansen SC. Rare disease partnership: the role of the 
US HAEA in angioedema care. Immunol Allergy Clin North Am. 
2013;33(4):545–53.
 25. Riedl MA. Creating a comprehensive treatment plan for hereditary angi-
oedema. Immunol Allergy Clin North Am. 2013;33(4):471–85.
